United States - English - NLM (National Library of Medicine)

seqirus, inc. - influenza a virus a/idaho/07/2018 (h1n1) antigen (mdck cell derived, propiolactone inactivated (unii: z6y9y35soy) (influenza a virus a/idaho/07/2018 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:cj7119yk1w), influenza a virus a/indiana/08/2018 (h3n2) antigen (mdck cell derived, propiolactone inactivated) (unii: z5eje3ep8t) (influenza a virus a/indiana/08/2018 (h3n2) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:4t55w47jol), influenza b vir - flucelvax quadrivalent is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes a and type b contained in the vaccine. flucelvax quadrivalent is approved for use in persons 4 years of age and older. for children and adolescents 4 through 17 years of age, approval is based on the immune response elicited by flucelvax quadrivalent. data demonstrating a decrease in influenza disease after vaccination of this age group with flucelvax quadrivalent are not available. [see clinical studies (14)] do not administer flucelvax quadrivalent to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine [see description (11) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to flucelvax quadrivalent during pregnancy. women who are vaccinated with flucelvax quadrivalent during pregnancy are encouraged to enroll in the registry by calling

United States - English - NLM (National Library of Medicine)

seqirus inc. - influenza a virus a/nebraska/14/2019 (h1n1) antigen (mdck cell derived, propiolactone inactivated) (unii: ezq32tf2as) (influenza a virus a/nebraska/14/2019 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:jtd2pe1hfr), influenza a virus a/delaware/39/2019 (h3n2) antigen (mdck cell derived, propiolactone inactivated) (unii: 5mir93vlg8) (influenza a virus a/delaware/39/2019 (h3n2) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:jx3jfh4h9s), influe - flucelvax quadrivalent is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes a and types b contained in the vaccine. flucelvax quadrivalent is approved for use in persons 2 years of age and older. [see clinical studies (14)] do not administer flucelvax quadrivalent to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are insufficient data for flucelvax quadrivalent in pregnant women to inform vaccine-associated risks in pregnancy. there were no developmental toxicity studies of flucelvax quadrivalent performed in animals. a developmental toxicity study has been performed in female ra

United States - English - NLM (National Library of Medicine)

seqirus inc. - influenza a virus a/washington/19/2020 (h1n1) antigen (mdck cell derived, propiolactone inactivated) (unii: 3yn85tu9mj) (influenza a virus a/washington/19/2020 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:32ss7wu2j7), influenza a virus a/tasmania/503/2020 (h3n2) antigen (mdck cell derived, propiolactone inactivated) (unii: 6er9j3gb63) (influenza a virus a/tasmania/503/2020 (h3n2) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:bun3xfj2b3), - flucelvax quadrivalent is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes a and types b contained in the vaccine. flucelvax quadrivalent is approved for use in persons 6 months of age and older. [see clinical studies (14)] do not administer flucelvax quadrivalent to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are insufficient data for flucelvax quadrivalent in pregnant women to inform vaccine-associated risks in pregnancy. there were no developmental toxicity studies of flucelvax quadrivalent performed in animals. a developmental toxicity study has been performed in female r

United States - English - NLM (National Library of Medicine)

seqirus inc. - influenza a virus a/georgia/12/2022 cvr-167 (h1n1) antigen (mdck cell derived, propiolactone inactivated) (unii: b8p3xn76w4) (influenza a virus a/georgia/12/2022 cvr-167 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:n8jks3vk2a), influenza a virus a/darwin/11/2021 (h3n2) antigen (mdck cell derived, propiolactone inactivated) (unii: pv9k2r8hrm) (influenza a virus a/darwin/11/2021 (h3n2) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:c6pm4nxj3 - flucelvax quadrivalent is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes a and types b contained in the vaccine. flucelvax quadrivalent is approved for use in persons 6 months of age and older. [see clinical studies (14)] do not administer flucelvax quadrivalent to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data collected in a prospective pregnancy exposure registry from 665 women vaccinated with flucelvax quadrivalent showed no evidence of a vaccine-associated increase in the risk of major birth defects and miscarriages when flucelvax quadrivalent is administered during any trime

India - English - Central Drugs Standard Control Organization

mdc ph. - tramadol hcl.,paracetamol - tab - 37.5,325;mg - 10

India - English - Central Drugs Standard Control Organization

mdc ph. - od tab - 10

India - English - Central Drugs Standard Control Organization

mdc ph. - alfacalcidol,elemental calcium - tab - 0.25mcg,200mg - 10

India - English - Central Drugs Standard Control Organization

mdc ph. - azithromycin - tab - 250/500;mg - 10/10

India - English - Central Drugs Standard Control Organization

mdc ph. - diclofenac pot.,serratiopeptidase - tab - 50,10;mg - 10

India - English - Central Drugs Standard Control Organization

mdc ph. - syr - 100ml